잠시만 기다려 주세요. 로딩중입니다.

Cannabidiol for Treating Lennox-Gastaut Syndrome and Dravet Syndrome in Korea

Journal of Korean Medical Science 2020년 35권 50호 p.427 ~ 427
구청모, 김세희, 이준수, 박병주, 이해국, 김흥동, 강훈철,
소속 상세정보
구청모 ( Koo Chung-Mo ) - Yonsei University College of Medicine Severance Children’s Hospital Department of Pediatrics
김세희 ( Kim Se-Hee ) - Yonsei University College of Medicine Severance Children’s Hospital Department of Pediatrics
이준수 ( Lee Joon-Soo ) - Yonsei University College of Medicine Severance Children’s Hospital Department of Pediatrics
박병주 ( Park Byung-Joo ) - Seoul National University College of Medicine Department of Preventive Medicine
이해국 ( Lee Hae-Kook ) - Catholic University College of Medicine Department of Psychiatry
김흥동 ( Kim Heung-Dong ) - Yonsei University College of Medicine Severance Children’s Hospital Department of Pediatrics
강훈철 ( Kang Hoon-Chul ) - Yonsei University College of Medicine Severance Children’s Hospital Department of Pediatrics

Abstract


Background: For the first time in Korea, we aimed to study the efficacy and safety of cannabidiol (CBD), which is emerging as a new alternative in treating epileptic encephalopathies.

Methods: This study was conducted retrospectively with patients between the ages of 2?18 years diagnosed with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) were enrolled from March to October 2019, who visited outpatient unit at 3 and 6 months to evaluate medication efficacy and safety based on caregiver reporting. Additional evaluations, such as electroencephalogram and blood tests, were conducted at each period also. CBD was administered orally at a starting dose of 5 mg/kg/day, and was maintained at 10 mg/kg/day.

Results: We analyzed 34 patients in the LGS group and 10 patients in the DS group between the ages of 1.2?15.8 years. In the 3-month evaluation, the overall reduction of seizure frequency in the LGS group was 52.9% (>50% reduction in 32.3% of the cases), and 29.4% in the 6-month evaluation (more than 50% reduction in 20.6%). In DS group, the reduction of seizure frequency by more than 50% was 30% and 20% in the 3-month and 6-month evaluation, respectively. Good outcomes were defined as the reduction of seizure frequency by more than 50% and similar results were observed in both LGS and DS groups. Adverse events were reported in 36.3% of total patients of which most common adverse events were gastrointestinal problems. However, no life-threatening adverse event was reported in both LGS and DS during the observation period.

Conclusion: In this first Korean study, CBD was safe and tolerable for use and could be expected to potentially reduce the seizure frequency in pediatric patients with LGS or DS.

키워드

Cannabidiol; Lennox Gastaut Syndrome; Dravet Syndrome

원문 및 링크아웃 정보

 

등재저널 정보